NEW YORK (GenomeWeb News) – Fluidigm today announced its collaboration with Novartis to develop a non-invasive fetal diagnostic test has ended.

The collaboration ended on May 1, when Novartis chose not to exercise an option to exclusively license Fluidigm's digital PCR technology. Fluidgm added that it successfully achieved all of its technical feasibility milestones in the first phase of the collaboration and received all milestone payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.